Cargando…

Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index

PURPOSE: Prognostic evaluation using interim positron emission tomography/computed tomography (interim PET/CT; I-PET) remains controversial. For any predictor, the prognosis of patients around its cutoff value is most uncertain. If the patients around the cutoff value could be subdivided by another...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hongwei, Yu, Zhan, Ma, Ning, Zhou, Jie, Tian, Rongrong, Zhao, Ming, Wang, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842747/
https://www.ncbi.nlm.nih.gov/pubmed/31807074
http://dx.doi.org/10.2147/CMAR.S218678
_version_ 1783468087142514688
author Sun, Hongwei
Yu, Zhan
Ma, Ning
Zhou, Jie
Tian, Rongrong
Zhao, Ming
Wang, Tong
author_facet Sun, Hongwei
Yu, Zhan
Ma, Ning
Zhou, Jie
Tian, Rongrong
Zhao, Ming
Wang, Tong
author_sort Sun, Hongwei
collection PubMed
description PURPOSE: Prognostic evaluation using interim positron emission tomography/computed tomography (interim PET/CT; I-PET) remains controversial. For any predictor, the prognosis of patients around its cutoff value is most uncertain. If the patients around the cutoff value could be subdivided by another factor, like the international prognostic index (IPI), it may improve the predictive power of I-PET. The combination of I-PET and IPI for risk stratification of patients was explored in this study. PATIENTS AND METHODS: One hundred and eleven diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP therapy were included retrospectively, 59 of whom underwent PET/CT after three or four cycles of treatment (I-PET). Fifty-two patients underwent PET/CT after five or six cycles of treatment (end of treatment; E-PET). RESULTS: When Deauville 5-point scale (5-DS) scores of 4–5 were classified as a positive scan (denoted by DS [score 4]), there was no significant difference in progression-free survival (PFS) between I-PET positive and negative patients (P=0.151). Further, patients with 5-DS score 3 and high IPI were stratified into I-PET positive-, whereas those with 5-DS score 3 and low IPI were classified into I-PET negative scan groups. Under this stratification, there was a significant difference in PFS between I-PET positive and negative patients (P=0.001). The sensitivity, positive predictive value, and negative predictive value for 2-year PFS for the combination score were higher than DS (score 4) alone (66.7% vs 33.3%, 50.0%vs 37.5%, 93.6% vs 88.2%) whereas specificity was almost the same (90.0% vs 88.0%). CONCLUSION: Subdivision of patients with 5-DS score 3 by IPI improved prognostic prediction accuracy. The IPI adds strength to 5-DS in I-PET to detect patients with good or poor prognosis. Compared with other combinations of I-PET and IPI, dividing the patients around the cutoff value of 5-DS by IPI was easily accepted by clinicians and allowed them to decide on further treatment practically.
format Online
Article
Text
id pubmed-6842747
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68427472019-12-05 Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index Sun, Hongwei Yu, Zhan Ma, Ning Zhou, Jie Tian, Rongrong Zhao, Ming Wang, Tong Cancer Manag Res Original Research PURPOSE: Prognostic evaluation using interim positron emission tomography/computed tomography (interim PET/CT; I-PET) remains controversial. For any predictor, the prognosis of patients around its cutoff value is most uncertain. If the patients around the cutoff value could be subdivided by another factor, like the international prognostic index (IPI), it may improve the predictive power of I-PET. The combination of I-PET and IPI for risk stratification of patients was explored in this study. PATIENTS AND METHODS: One hundred and eleven diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP therapy were included retrospectively, 59 of whom underwent PET/CT after three or four cycles of treatment (I-PET). Fifty-two patients underwent PET/CT after five or six cycles of treatment (end of treatment; E-PET). RESULTS: When Deauville 5-point scale (5-DS) scores of 4–5 were classified as a positive scan (denoted by DS [score 4]), there was no significant difference in progression-free survival (PFS) between I-PET positive and negative patients (P=0.151). Further, patients with 5-DS score 3 and high IPI were stratified into I-PET positive-, whereas those with 5-DS score 3 and low IPI were classified into I-PET negative scan groups. Under this stratification, there was a significant difference in PFS between I-PET positive and negative patients (P=0.001). The sensitivity, positive predictive value, and negative predictive value for 2-year PFS for the combination score were higher than DS (score 4) alone (66.7% vs 33.3%, 50.0%vs 37.5%, 93.6% vs 88.2%) whereas specificity was almost the same (90.0% vs 88.0%). CONCLUSION: Subdivision of patients with 5-DS score 3 by IPI improved prognostic prediction accuracy. The IPI adds strength to 5-DS in I-PET to detect patients with good or poor prognosis. Compared with other combinations of I-PET and IPI, dividing the patients around the cutoff value of 5-DS by IPI was easily accepted by clinicians and allowed them to decide on further treatment practically. Dove 2019-11-06 /pmc/articles/PMC6842747/ /pubmed/31807074 http://dx.doi.org/10.2147/CMAR.S218678 Text en © 2019 Sun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Hongwei
Yu, Zhan
Ma, Ning
Zhou, Jie
Tian, Rongrong
Zhao, Ming
Wang, Tong
Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
title Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
title_full Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
title_fullStr Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
title_full_unstemmed Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
title_short Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index
title_sort risk stratification of diffuse large b-cell lymphoma with interim pet/ct by combining deauville scores and international prognostic index
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842747/
https://www.ncbi.nlm.nih.gov/pubmed/31807074
http://dx.doi.org/10.2147/CMAR.S218678
work_keys_str_mv AT sunhongwei riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex
AT yuzhan riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex
AT maning riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex
AT zhoujie riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex
AT tianrongrong riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex
AT zhaoming riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex
AT wangtong riskstratificationofdiffuselargebcelllymphomawithinterimpetctbycombiningdeauvillescoresandinternationalprognosticindex